High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma

Shin Young Hyun, June Won Cheong, Soo Jeong Kim, Yoo Hong Min, Deok Hwan Yang, Jae Sook Ahn, Won Sik Lee, Hun Mo Ryoo, Young Rok Do, Ho Sup Lee, Jae Hoon Lee, Sung Yong Oh, Cheolwon Suh, Ho Young Yhim, Jin Seok Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemomobilization regimens: high-dose (HD) cyclophosphamide, HD etoposide (VP-16), and platinum-based chemotherapies. We reviewed the experiences of 10 institutions with 103 non-Hodgkin lymphoma patients who had previously only been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy. The mobilization yields for each regimen were analyzed. HD VP-16 mobilized a significantly higher median number of CD34+ cells (16.22× 106 cells/kg) than HD cyclophosphamide (4.44× 106 cells/kg) or platinum-based chemotherapies (6.08× 106 cells/kg, P < .001). The rate of successful mobilization (CD34+ cell count ≥5.0× 106 cells/kg) was also significantly higher for HD VP-16 (86%) than for HD cyclophosphamide (45%) or platinum-based chemotherapies (61%, P= .004). The successful mobilization rate on day 1 of 72% for HD VP-16 was significantly higher than the rates for HD cyclophosphamide (13%) and platinum-based chemotherapies (26%, P < .001). In multivariate analysis, HD VP-16 was a significant predictor of successful mobilization (P= .014; odds ratio, 5.25; 95% confidence interval, 1.40 to 19.63). Neutropenic fever occurred in 67% of patients treated with HD VP-16. The incidence was similar for HD cyclophosphamide (58%, P= .454) but was significantly lower for platinum-based chemotherapies (12%, P < .001). However, fatal (grade ≥ 4) infection and treatment-related mortality were not observed in this study. In conclusion, the mobilization yield was significantly influenced by the chemomobilization regimen, and HD VP-16 was a highly effective mobilization regimen in patients with non-Hodgkin lymphoma.

Original languageEnglish
Pages (from-to)73-79
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Etoposide
Non-Hodgkin's Lymphoma
Lymphoma
Cyclophosphamide
Drug Therapy
Platinum
Survival
Cell Count
Vincristine
Prednisone
Doxorubicin
Multicenter Studies
Fever
Multivariate Analysis
Retrospective Studies
Odds Ratio
Confidence Intervals
Mortality

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Hyun, Shin Young ; Cheong, June Won ; Kim, Soo Jeong ; Min, Yoo Hong ; Yang, Deok Hwan ; Ahn, Jae Sook ; Lee, Won Sik ; Ryoo, Hun Mo ; Do, Young Rok ; Lee, Ho Sup ; Lee, Jae Hoon ; Oh, Sung Yong ; Suh, Cheolwon ; Yhim, Ho Young ; Kim, Jin Seok. / High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy : A Study from the Consortium for Improving Survival of Lymphoma. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 1. pp. 73-79.
@article{e85a33fa5a3d40fcb4528c20a9eab98b,
title = "High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma",
abstract = "We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemomobilization regimens: high-dose (HD) cyclophosphamide, HD etoposide (VP-16), and platinum-based chemotherapies. We reviewed the experiences of 10 institutions with 103 non-Hodgkin lymphoma patients who had previously only been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy. The mobilization yields for each regimen were analyzed. HD VP-16 mobilized a significantly higher median number of CD34+ cells (16.22× 106 cells/kg) than HD cyclophosphamide (4.44× 106 cells/kg) or platinum-based chemotherapies (6.08× 106 cells/kg, P < .001). The rate of successful mobilization (CD34+ cell count ≥5.0× 106 cells/kg) was also significantly higher for HD VP-16 (86{\%}) than for HD cyclophosphamide (45{\%}) or platinum-based chemotherapies (61{\%}, P= .004). The successful mobilization rate on day 1 of 72{\%} for HD VP-16 was significantly higher than the rates for HD cyclophosphamide (13{\%}) and platinum-based chemotherapies (26{\%}, P < .001). In multivariate analysis, HD VP-16 was a significant predictor of successful mobilization (P= .014; odds ratio, 5.25; 95{\%} confidence interval, 1.40 to 19.63). Neutropenic fever occurred in 67{\%} of patients treated with HD VP-16. The incidence was similar for HD cyclophosphamide (58{\%}, P= .454) but was significantly lower for platinum-based chemotherapies (12{\%}, P < .001). However, fatal (grade ≥ 4) infection and treatment-related mortality were not observed in this study. In conclusion, the mobilization yield was significantly influenced by the chemomobilization regimen, and HD VP-16 was a highly effective mobilization regimen in patients with non-Hodgkin lymphoma.",
author = "Hyun, {Shin Young} and Cheong, {June Won} and Kim, {Soo Jeong} and Min, {Yoo Hong} and Yang, {Deok Hwan} and Ahn, {Jae Sook} and Lee, {Won Sik} and Ryoo, {Hun Mo} and Do, {Young Rok} and Lee, {Ho Sup} and Lee, {Jae Hoon} and Oh, {Sung Yong} and Cheolwon Suh and Yhim, {Ho Young} and Kim, {Jin Seok}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2013.10.012",
language = "English",
volume = "20",
pages = "73--79",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy : A Study from the Consortium for Improving Survival of Lymphoma. / Hyun, Shin Young; Cheong, June Won; Kim, Soo Jeong; Min, Yoo Hong; Yang, Deok Hwan; Ahn, Jae Sook; Lee, Won Sik; Ryoo, Hun Mo; Do, Young Rok; Lee, Ho Sup; Lee, Jae Hoon; Oh, Sung Yong; Suh, Cheolwon; Yhim, Ho Young; Kim, Jin Seok.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 1, 01.01.2014, p. 73-79.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy

T2 - A Study from the Consortium for Improving Survival of Lymphoma

AU - Hyun, Shin Young

AU - Cheong, June Won

AU - Kim, Soo Jeong

AU - Min, Yoo Hong

AU - Yang, Deok Hwan

AU - Ahn, Jae Sook

AU - Lee, Won Sik

AU - Ryoo, Hun Mo

AU - Do, Young Rok

AU - Lee, Ho Sup

AU - Lee, Jae Hoon

AU - Oh, Sung Yong

AU - Suh, Cheolwon

AU - Yhim, Ho Young

AU - Kim, Jin Seok

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemomobilization regimens: high-dose (HD) cyclophosphamide, HD etoposide (VP-16), and platinum-based chemotherapies. We reviewed the experiences of 10 institutions with 103 non-Hodgkin lymphoma patients who had previously only been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy. The mobilization yields for each regimen were analyzed. HD VP-16 mobilized a significantly higher median number of CD34+ cells (16.22× 106 cells/kg) than HD cyclophosphamide (4.44× 106 cells/kg) or platinum-based chemotherapies (6.08× 106 cells/kg, P < .001). The rate of successful mobilization (CD34+ cell count ≥5.0× 106 cells/kg) was also significantly higher for HD VP-16 (86%) than for HD cyclophosphamide (45%) or platinum-based chemotherapies (61%, P= .004). The successful mobilization rate on day 1 of 72% for HD VP-16 was significantly higher than the rates for HD cyclophosphamide (13%) and platinum-based chemotherapies (26%, P < .001). In multivariate analysis, HD VP-16 was a significant predictor of successful mobilization (P= .014; odds ratio, 5.25; 95% confidence interval, 1.40 to 19.63). Neutropenic fever occurred in 67% of patients treated with HD VP-16. The incidence was similar for HD cyclophosphamide (58%, P= .454) but was significantly lower for platinum-based chemotherapies (12%, P < .001). However, fatal (grade ≥ 4) infection and treatment-related mortality were not observed in this study. In conclusion, the mobilization yield was significantly influenced by the chemomobilization regimen, and HD VP-16 was a highly effective mobilization regimen in patients with non-Hodgkin lymphoma.

AB - We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemomobilization regimens: high-dose (HD) cyclophosphamide, HD etoposide (VP-16), and platinum-based chemotherapies. We reviewed the experiences of 10 institutions with 103 non-Hodgkin lymphoma patients who had previously only been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy. The mobilization yields for each regimen were analyzed. HD VP-16 mobilized a significantly higher median number of CD34+ cells (16.22× 106 cells/kg) than HD cyclophosphamide (4.44× 106 cells/kg) or platinum-based chemotherapies (6.08× 106 cells/kg, P < .001). The rate of successful mobilization (CD34+ cell count ≥5.0× 106 cells/kg) was also significantly higher for HD VP-16 (86%) than for HD cyclophosphamide (45%) or platinum-based chemotherapies (61%, P= .004). The successful mobilization rate on day 1 of 72% for HD VP-16 was significantly higher than the rates for HD cyclophosphamide (13%) and platinum-based chemotherapies (26%, P < .001). In multivariate analysis, HD VP-16 was a significant predictor of successful mobilization (P= .014; odds ratio, 5.25; 95% confidence interval, 1.40 to 19.63). Neutropenic fever occurred in 67% of patients treated with HD VP-16. The incidence was similar for HD cyclophosphamide (58%, P= .454) but was significantly lower for platinum-based chemotherapies (12%, P < .001). However, fatal (grade ≥ 4) infection and treatment-related mortality were not observed in this study. In conclusion, the mobilization yield was significantly influenced by the chemomobilization regimen, and HD VP-16 was a highly effective mobilization regimen in patients with non-Hodgkin lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=84890961475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890961475&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.10.012

DO - 10.1016/j.bbmt.2013.10.012

M3 - Article

C2 - 24141009

AN - SCOPUS:84890961475

VL - 20

SP - 73

EP - 79

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -